Risk factor
Negligible price volatility
Profitability factor
Greatly overvalued vs peers
About
Established in 1996 and headquartered in Gurugram, India, Fortis Healthcare Limited operates as an integrated provider of healthcare services. The company extends its offerings, which encompass secondary, tertiary, and quaternary medical care, across India, the United Arab Emirates, Sri Lanka, and other international markets. Its diverse healthcare infrastructure includes a network of hospitals, diagnostic facilities, and specialized day-care centers. Fortis delivers expertise across a broad spectrum of medical disciplines, including cardiology, cosmetic and dental sciences, dermatology, endocrinology, emergency medicine, ENT, fetal medicine, gastroenterology and hepatology, general surgery, haematology, infertility treatment, internal medicine, mental and behavioral health, nephrology, neurosurgery, neurointervention, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy, plastic surgery, pulmonology, radiology, rheumatology, thoracic surgery, transplant medicine, urology, and numerous other supporting specialties. By March 31, 2022, the company managed 26 hospitals, housing approximately 4,300 operational beds, in addition to around 426 diagnostic centers and laboratories, complemented by 2,550 collection centers.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Target Price
The average target price of FORTIS.NS is 1091 and suggests 19.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to